• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    6/21/24 2:04:00 PM ET
    $AAGR
    $ABL
    $ADTN
    $ALUR
    Farming/Seeds/Milling
    Consumer Staples
    Investment Managers
    Finance
    Get the next $AAGR alert in real time by email

    Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering.

    Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit.

    Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday.

    Here are some other stocks moving in today’s mid-day session.

    Gainers

    • American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors.
    • Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) shares surged 73% to $0.5883. The company recently announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.
    • Minim, Inc. (NASDAQ:MINM) gained 48% to $4.2389.
    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose 39.2% to $171.89 after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
    • Mustang Bio, Inc. (NASDAQ:MBIO) gained 36.5% to $0.7661. Mustang Bio recently announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) shares climbed 31% to $1.35 following insider buying from the company's co-founder. After the market close on Thursday, Clover Health filed a Form 4 with the SEC showing that co-founder and executive chair Vivek Garipalli purchased 877,567 shares of Clover Health stock at an average price of $1.14 per share.
    • Orgenesis Inc. (NASDAQ:ORGS) rose 29.4% to $0.58.
    • 36Kr Holdings Inc. (NASDAQ:KRKR) gained 26% to $0.4342 after the company announced that it has entered into a strategic partnership with SenseTime.
    • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 25% to $0.2196.
    • Eco Wave Power Global AB (publ) (NASDAQ:WAVE) gained 21.3% to $2.68.
    • Universe Pharmaceuticals INC (NASDAQ:UPC) gained 19.9% to $2.7699.
    • Nexalin Technology, Inc. (NASDAQ:NXL) rose 19% to $1.3150. Nexalin Technology was recently awarded a patent by the USPTO related to its deep intracranial frequency stimulation device for the treatment of Alzheimer’s and dementia.
    • Gossamer Bio, Inc. (NASDAQ:GOSS) jumped 17% to $0.6637.
    • Avid Bioservices, Inc. (NASDAQ:CDMO) rose 13.7% to $7.75.
    • DermTech, Inc. (NASDAQ:DMTK) gained 13.5% to $0.1337 after declining 19% on Thursday. DermTech recently filed for Chapter 11 protection and implemented a 20% workforce reduction to preserve cash.
    • Asana, Inc. (NYSE:ASAN) rose 13.4% to $12.90 after the company announced a $150 million stock repurchase program.
    • Trinity Place Holdings Inc. (NYSE:TPHS) shares rose 12.2% to $0.1440 after gaining more than 5% on Thursday.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) gained 9.1% to $9.09.
    • ADTRAN Holdings, Inc. (NASDAQ:ADTN) rose 8.7% to $5.65
    • Hertz Global Holdings, Inc. (NASDAQ:HTZ) climbed 8.6% to $3.8150. The company revealed the upsize and pricing of $1 billion offerings, which comprised $750 million of First Lien Senior Secured Notes, which represents an upsize from the previously announced $500 million.
    • Zoomcar Holdings, Inc. (NASDAQ:ZCAR) rose 7.5% to $0.1570. Zoomcar announced closing of sale of $3.6 million notes private placement.

    Losers

    • Psyence Biomedical Ltd. (NASDAQ:PBM) shares dipped 36% to $0.3820 after gaining 6% on Thursday.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) shares fell 23.1% to $0.5012 after dipping around 14% on Thursday.
    • Reliance Global Group, Inc. (NASDAQ:RELI) shares fell 22.8% to $0.4668. Reliance Global shares jumped 54% on Thursday after the company announced an institutional investor has redeemed all of its outstanding Series B and Series G warrants.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) dipped 22.5% to $0.5008.
    • Crown Electrokinetics Corp. (NASDAQ:CRKN) declined 21.8% to $0.0391 after the company announced a 1-for-150 reverse stock split.
    • Allurion Technologies Inc. (NYSE:ALUR) fell 21.5% to $2.0399. Allurion Technologies, on Thursday, announced the publication of a new study showing patients on its Allurion Program experienced an average weight loss of 14% and an average lean mass gain of 5.6% over four months.
    • Brand Engagement Network, Inc. (NASDAQ:BNAI) fell 20.2% to $2.89.
    • African Agriculture Holdings Inc. (NASDAQ:AAGR) declined 18% to $0.2376
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 17% to $0.1335 after gaining 35% on Thursday.
    • NANO Nuclear Energy Inc. (NASDAQ:NNE) shares fell 13.2% to $13.21 after surging 31% on Thursday.
    • SmartKem, Inc. (NASDAQ:SMTK) fell 12.8% to $5.36.
    • Molecular Partners AG (NASDAQ:MOLN) shares dipped 12.3% to $9.66 after jumping over 38% on Thursday.
    • Applied Digital Corporation (NASDAQ:APLD) fell 12% to $5.32.
    • Cipher Mining Inc. (NASDAQ:CIFR) declined 11.5% to $4.6350.
    • Smith & Wesson Brands, Inc. (NASDAQ:SWBI) fell 10.7% to $14.65 after the company reported quarterly earnings.
    • Abacus Life, Inc. (NASDAQ:ABL) shares declined 10.3% to $8.75 as the company priced $80 million public offering of 10 million common stock at $8 per share.
    • Trex Company, Inc. (NYSE:TREX) dipped 7.7% to $77.59.
    • Bloom Energy Corporation (NYSE:BE) fell 6.3% to $13.14.

    Now Read This: Wall Street’s Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

    Get the next $AAGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAGR
    $ABL
    $ADTN
    $ALUR

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Trex Company Inc.
    $TREX
    2/25/2026$53.00Hold → Buy
    Loop Capital
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Bloom Energy Corporation
    $BE
    2/24/2026$162.00Neutral
    Citigroup
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Trex Company Inc.
    $TREX
    2/11/2026Buy → Hold
    The Benchmark Company
    Cipher Digital Inc.
    $CIFR
    2/9/2026$38.00Overweight
    Morgan Stanley
    More analyst ratings

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rose B Andrew bought $503,560 worth of shares (12,380 units at $40.68), increasing direct ownership by 687% to 14,183 units (SEC Form 4)

    4 - TREX CO INC (0001069878) (Issuer)

    3/3/26 4:37:59 PM ET
    $TREX
    Forest Products
    Basic Materials

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAGR
    $ABL
    $ADTN
    $ALUR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Page Tyler

    4 - Cipher Digital Inc. (0001819989) (Issuer)

    3/27/26 5:59:33 PM ET
    $CIFR
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Sin Hendrick

    3 - 36Kr Holdings Inc. (0001779476) (Issuer)

    3/27/26 10:11:03 AM ET
    $KRKR
    Real Estate

    SEC Form 4 filed by Colendich Katie Marie

    4 - Asana, Inc. (0001477720) (Issuer)

    3/26/26 5:06:11 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    The U.S. Imports ~95% of Its Uranium. One of the Largest Domestic Deposits Just Engaged a Highly Experienced Permitting Team

    NUCL, UUUU, UROY, BWXT, and NNE as Domestic Nuclear Supply Chains Move From Policy to Permitting Issued on behalf of Eagle Nuclear Energy Corp. Companies mentioned in this article: Eagle Nuclear Energy Corp. (NASDAQ:NUCL), Energy Fuels (NYSE:UUUU), Uranium Royalty Corp. (NASDAQ:UROY), BWX Technologies (NYSE:BWXT), Nano Nuclear Energy (NASDAQ:NNE) Key Takeaways:• Eagle Nuclear Energy Corp. (NASDAQ:NUCL) has engaged SLR International Corporation as lead permitting manager for the Aurora Uranium Project — the largest conventional, measured and indicated uranium deposit in the United States, with 32.75M lbs indicated and 4.98M lbs inferred.• The U.S. imports approximately 95% of the uranium i

    3/27/26 9:15:00 AM ET
    $BWXT
    $NNE
    $NUCL
    Industrial Machinery/Components
    Industrials
    Electric Utilities: Central
    Utilities

    Bloom Energy Appoints Simon Edwards as Chief Financial Officer

    Bloom Energy (NYSE:BE), a global leader in onsite power solutions, today announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13, 2026. A seasoned finance executive with nearly two decades of experience scaling technology companies, Edwards brings a rare combination of operational rigor, systems leadership, and deep exposure to digital infrastructure that aligns with Bloom's strength, market focus and strategy – to be a solution for power availability as it becomes the defining constraint on the AI industry and its growth. Edwards joins Bloom from AI-inference leader Groq, where he most recently served as CEO after initially joining as CFO. At Groq, he le

    3/26/26 4:05:00 PM ET
    $BE
    Industrial Machinery/Components
    Energy

    $AAGR
    $ABL
    $ADTN
    $ALUR
    SEC Filings

    View All

    SEC Form PRE 14A filed by Bloom Energy Corporation

    PRE 14A - Bloom Energy Corp (0001664703) (Filer)

    3/27/26 4:11:21 PM ET
    $BE
    Industrial Machinery/Components
    Energy

    Amendment: SEC Form SCHEDULE 13G/A filed by Trex Company Inc.

    SCHEDULE 13G/A - TREX CO INC (0001069878) (Subject)

    3/27/26 1:36:10 PM ET
    $TREX
    Forest Products
    Basic Materials

    Amendment: SEC Form SCHEDULE 13G/A filed by Smith & Wesson Brands Inc.

    SCHEDULE 13G/A - SMITH & WESSON BRANDS, INC. (0001092796) (Subject)

    3/27/26 1:18:02 PM ET
    $SWBI
    Ordnance And Accessories
    Industrials

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trex upgraded by Loop Capital with a new price target

    Loop Capital upgraded Trex from Hold to Buy and set a new price target of $53.00

    2/25/26 7:18:28 AM ET
    $TREX
    Forest Products
    Basic Materials

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Financials

    Live finance-specific insights

    View All

    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need

    3/24/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Digital Sets Fiscal Third Quarter 2026 Conference Call for Wednesday, April 8, 2026, at 5:00 p.m. Eastern Time

    DALLAS, March 19, 2026 (GLOBE NEWSWIRE) -- Applied Digital Corporation (NASDAQ:APLD) ("Applied Digital" or the "Company"), a leading designer, builder and operator of high-performance, sustainably engineered data centers and colocation services for Artificial Intelligence ("AI"), networking, and blockchain workloads, will host a conference call on Wednesday, April 8, 2026, at 5:00 p.m. Eastern Time to discuss its operations and financial results for the fiscal third quarter ended February 28, 2026. A press release detailing these results will be issued after the market closes on the same day. Applied Digital management will provide prepared remarks, followed by a question-and-answer perio

    3/19/26 4:05:00 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $AAGR
    $ABL
    $ADTN
    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Bloom Energy Appoints Simon Edwards as Chief Financial Officer

    Bloom Energy (NYSE:BE), a global leader in onsite power solutions, today announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13, 2026. A seasoned finance executive with nearly two decades of experience scaling technology companies, Edwards brings a rare combination of operational rigor, systems leadership, and deep exposure to digital infrastructure that aligns with Bloom's strength, market focus and strategy – to be a solution for power availability as it becomes the defining constraint on the AI industry and its growth. Edwards joins Bloom from AI-inference leader Groq, where he most recently served as CEO after initially joining as CFO. At Groq, he le

    3/26/26 4:05:00 PM ET
    $BE
    Industrial Machinery/Components
    Energy

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana to Appoint Aziz Megji to the Role of Chief Financial Officer

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), the system of action where humans and AI run work together, will promote Aziz Megji to the role of Chief Financial Officer (CFO), effective March 24, 2026. Megji will succeed Sonalee Parekh, who has served as Asana's CFO since 2024 and tendered her resignation effective March 23, 2026. Megji brings his experience from his Head of Financial Planning & Analysis role where he led the company's annual planning, budgeting, forecasting, and performance management processes, as well as overseeing the strategic finance, treasury, investor relations, corporate development, deal desk, and sales compensation functions. He partners closely with Asana's CEO and Boa

    3/2/26 4:06:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology